• Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact

Barry A. Friedman, PhD LLC

FDA Regulatory Compliance for the Pharmaceutical, Biotechnology and Medical Device Arenas

TRIAD GROUP RAIDED BY U.S. MARSHAL SERVICE (APRIL 4, 2011)

April 5, 2011 By Barry Friedman Leave a Comment

TRIAD GROUP RAIDED BY U.S. MARSHAL SERVICE (APRIL 4, 2011) 

See also new FDA-483 from March 28, 2011 (Link attached below)

HARTLAND, Wis.—

A medical products maker in Hartland ceased production Monday after the U.S. Marshals Service arrived to quarantine or seize materials. 

The Milwaukee Journal Sentinel reports H&P Industries, which makes alcohol wipes and other products under the name Triad Group, has been under investigation by the Food and Drug Administration.

Last week, the FDA asked H&P Industries to voluntarily stop production of its drug products.

A Triad Group spokeswoman confirms that production was stopped Monday and that U.S. marshals were there. 

In addition, another FDA -483 was issued as a result of an audit from March 21 – March 28, 2011 (see attached link below: http://www.fda.gov/downloads/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/UCM249480.pdf)

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)

Related

Filed Under: 483, FDA Compliance, Recall Tagged With: Bacillus cereus, FDA 483, quarantine, seizure, Triad Group, Triad Group Raided, U.S. Marshall Service

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

New Reader? Learn More

Connect With Me:

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Webinar Registration & Information

FREQUENTLY ASKED QUESTIONS:

FDA Form 483 Frequently Asked Questions

USP General Chapter

USP General Chapter 62, Part II

TOP OBSERVATIONS:

FDA’s CDER LISTING OF TOP NINETEEN OBSERVATIONS FOR 2014

FDA CDER Most Frequent Form FDA 483 Observations Fiscal Year 2012

CDER MOST FREQUENTLY CITED DRUG OBSERVATIONS – FISCAL YEAR 2010

Top Posts:

Top Posts for 2012

Top Posts for 2013

Top Posts Year To Date

Recent Posts

  • Upcoming Microbiological Webinars
  • Microbiological Webinars
  • Microbiological Webinars 2020 (Upcoming)
  • General Chapter (USP<60>) on B. cepacia Complex to Issue December 1, 2019
  • Les Produits Chimiques B.G.R., Inc. Receives FDA Warning Letter (07/24/2018) for Failure to Perform Laboratory Testing

Categories

follow us in feedly
  • Home
  • About
  • UPCOMING WEBINARS & SEMINARS
  • Consultation
  • USP 61/62 FAQ
  • Contact
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter

Thank You For Visiting Barry A. Friedman, PhD LLC - 2015

Welcome To My Blog!
Please enter your name and email below to receive my newsletter.
Your information will *never* be shared or sold to a 3rd party.